Quest diagnostics logo

American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Haystack Oncology, a Quest Diagnostics® company, is excited to attend the 2024 American Society of Clinical Oncology (ASCO) meeting May 31–June 4 in Chicago, IL. The 2024 ASCO conference will feature more than 200 sessions based on the theme, “The Art and Science of Cancer Care: From Comfort to Cure.” Learn more about ASCO 2024.

Visit our booth (#35145) to learn about Haystack MRD™, our next-generation minimal residual disease (MRD) test that delivers exceptional sensitivity, and meet our experts in precision oncology.

Meet our experts at ASCO—Saturday, June 1 from 3–4 PM at booth #35145

We’ve scheduled a time to ensure that you can catch our oncology experts. Quest offers a single solution that brings seamless access along the cancer care continuum, including a comprehensive genomic portfolio of more than 500 genes, MRD testing to support enhanced treatment decisions, and patient survivorship support. Don’t forget to mark your calendars and come prepared with questions. Hope to see you there!


Attend Dr Jeanne Tie’s update on the DYNAMIC study

Dr Jeanne Tie from the Peter MacCallum Cancer Centre in Melbourne, Australia is the first author on the DYNAMIC study that was presented 2 years ago, which was the first prospective, randomized controlled trial to demonstrate the clinical utility of MRD testing to help guide adjuvant treatment decisions. Haystack MRD uses an optimized version of the ctDNA detection technology used in the DYNAMIC study. Dr Tie is presenting 5-year results from that study at ASCO. 

  • Abstract title: “Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial”
  • Track: Special Sessions, Gastrointestinal Cancer
  • Abstract: 108
  • Session type: Clinical Science Symposium
  • Time: June 3, 10:37 AM to 10:49 AM

About Haystack MRD

Next-generation ctDNA detection with exquisite sensitivity and specificity for precise MRD reporting

Haystack MRD is a tumor-informed ctDNA detection test for postsurgical measurement of residual disease in solid tumor settings. The test is powered by sequencing chemistry that significantly reduces noise to detect even the least-abundant ctDNA molecules in blood. This unique ability translates to better minimal residual disease (MRD) detection for greater confidence when making key clinical decisions.

Purpose-built MRD technology developed by pioneers of cancer research

Haystack MRD was designed specifically for ultrasensitive ctDNA detection when testing for residual, recurrent, and resistant disease. Better sensitivity means the right patients are more likely to receive the right treatment at the right time, which can significantly improve outcomes and quality of life for patients who have been diagnosed with cancer.

Backed by the power of Quest

Haystack MRD offers end-to-end MRD test reliability, powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, and technology. Plus, the transition between Haystack MRD and Quest’s other advanced oncology testing is seamless, providing ease and convenience in the testing process for doctors and patients.

This test was developed and its analytical performance characteristics have been determined by Haystack Oncology. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes

Share:
Facebook
Twitter
LinkedIn
Email

Subscribe for updates

No spam, notifications only about new products, updates.
News and events

American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Haystack MRD™ by Quest Diagnostics® will be attending the 2024 American Association for Cancer Research (AACR) annual meeting taking place April 5–10, 2024 in San Diego, CA. The AACR annual meeting stands as the cornerstone of the cancer research community,

Follow us on social media

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Visit Johns Hopkins School of Medicine to learn more.
Visit Johns Hopkins School of Medicine to learn more.
Visit Johns Hopkins School of Medicine to learn more.